Ketan Parekh

In its interim order dated January 3, 2025, SEBI accused Salgaocar of benefiting from advance knowledge of large trade orders and barred him, Parekh, and others from trading.

Rohit Salgaocar blames Ketan Parekh in front running case, SAT to continue hearing tomorrow

Salgaocar had sought permission to cross examine Ketan Parekh, which SEBI had rejected later Salgacar moved SAT, challenging the rejection of his request.

Rohit Salgaocar moves SAT as SEBI denies cross examination of Ketan Parekh in front-running probe

Salgaocar’s petition also says that SEBI’s interim order has damaged his reputation and is threatening his livelihood. Matter is pending before SAT for hearing.

Sebi court bars Ketan Parekh from foreign travel, says he may misuse the permission

Parekh had cited family reasons in his plea, including attending a relative’s wedding, but Sebi he has in the past "used the travel permission as a cloak to disguised ongoing illegal activity".

Sebi Special Court rejects Ketan Parekh’s plea to travel abroad

Interestingly, the Sebi Special Court had permitted Parekh last year to travel abroad between December 20, 2024, and March 20, 2025, to destinations such as the UK, UAE, Singapore, Thailand, Sri Lanka, Japan and the EU.

Dark pool platforms under focus post-Sebi’s Ketan Parekh order

Several FPIs are using these platforms to find counterparties for trades

Ketan Parekh and associates had frontrun US-based Capital Group's funds, say sources

There was much speculation that the big client mentioned in the SEBI order was another fund, based on PB Fintech's stock in 2022

Ketan Parekh was front-running trades of Tiger Global, reveals exchange data

Data from BSE and NSE confirms that Tiger Global and a fund owned by the US-based investment firm sold shares of PB Fintech on November 11, 2022. Sebi's order against Ketan Parekh and others included screenshots of chats of trading instructions given on November 11 to sell shares of PB Fintech.

How angadias were used to split profits in Ketan Parekh's front-running op

Currency notes were crucial to this operation, serving as ID proofs

Rishte mei hum tumhare baap lagte hain, naam hai SEBI: How the regulator nailed Ketan Parekh

The market regulator used thrilling inventiveness to establish the connection between Ketan Parekh and the various numbers he was using to hide his identity

Ketan Parekh strikes again! SEBI unearths unusual front-running scam, impounds Rs 65.77 crore

SEBI passed an order on January 2, detailing an unusual scam

Are markets in bubble valuation territory?

Industrialist Harsh Goenka caused a mini flutter when he alleged share price manipulation by promoters in collusion with brokers. Is there merit in his allegations?

Stock broker Ketan Parekh sentenced for 2 years

The case relates to cheating committed by Parekh in alleged criminal conspiracy with the then Senior Manager of NRI Cell and Incharge of Safe Custody Department, Bank of Baroda, Mumbai and others.

Sebi@25: Greater powers after the Harshad Mehta scam

In the second part of the special series Sebi@ 25, CNBC-TV18‘s Ashmit Kumar reveals details how the market regulator learnt from these lapses and emerged keener and stronger

Ban on MITL for trades with Ketan Parekh related entities

Market regulator Sebi has barred Mascon Information Technologies Ltd (MITL) from the securities market for a period of two years for alleged fraudulent trading by way of offloading shares through off market transfers to Ketan Parekh related entities.

Why Sebi ban has helped Ketan Parekh more than hurting him

when the market revived in 2003, Parekh is learnt to have resumed trading using fronts. And the only way his erstwhile brokers could hope to recoup the money he owed them was to execute his transactions. These deals were on a profit sharing basis. If Parekh profited on the trade, a chunk of that money would go towards repaying the debt.

What is Lupin's acquisition agenda for the future?

Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.